



Predictive Alzheimer's Risk Screening through the Power of AI

ALZAI HEALTH CORPORATION | PRESENTATION 2025



Legal Disclaimer

THIS MANAGEMENT PRESENTATION (The "presentation") was prepared as a summary overview only of the current affairs of Alzai Health Corp. ("Alzai Health" or the "Company") and was not prepared for the purpose of assisting prospective investors in making a decision to invest in Alzai Health. Information disclosed in this presentation is current as of Q3 2025, except as otherwise provided herein, and Alzai Health does not undertake or agree to update this presentation after the date hereof. All information contained in this presentation is derived solely from management of Alzai Health and otherwise publicly available third-party information that has not been independently verified by the company. Further, the company does not make any representation as to the completeness, truth or accuracy of the information contained in this presentation. The company expressly warns readers not to rely on the information contained herein as advice (legal, financial, tax or otherwise) to current or potential investors. Accordingly, any use of this information is at your risk and without liability to the company. This presentation does not constitute and should not be construed as either a public or private offer to sell or the solicitation of an offer to purchase securities in the capital stock of Alzai Health in any jurisdiction in which such offer, solicitation or sale would be unlawful. Each prospective investor should contact his/her or its own legal adviser, independent financial adviser or tax adviser for legal, financial or tax advice regarding investment related decisions respecting the securities of the company. No person has been authorized to give any information or make any representation other than those contained in this presentation and, if given and/or made, such information or representations must not be relied upon as having been so authorized.

FORWARD-LOOKING INFORMATION This Presentation contains certain statements, which may constitute "forward-looking information" within the meaning of Canadian securities law requirements. Forward-looking information involves statements that are not based on historical information but rather relate to future operations, strategies, financial results or other developments. Forward-looking information is necessarily based upon estimates and assumptions, which are inherently subject to significant business, economic and competitive uncertainties and contingencies, many of which are beyond Alzai Health's control and many of which, regarding future business decisions, are subject to change. These uncertainties and contingencies can affect actual results and could cause actual results to differ materially from those expressed in any forward-looking statements made by or on Alzai Health's behalf. Although Alzai Health has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking information, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended. All factors should be considered carefully, and readers should not place undue reliance on Alzai Health's forward-looking information. Examples of such forward-looking information within this Presentation include statements relating to future capital expenditures, success of research activities, and government regulations. Generally, forward-looking information can be identified by the use of forward-looking terminology such as "expects," "estimates," "anticipates," or variations of such words and phrases (including negative and grammatical variations) or statements that certain actions, events or results "may," "could," "might" or "occur."

FORWARD-LOOKING STATEMENTS are not guarantees of future performance and involve risks, uncertainties and assumptions, which are difficult to predict. Assumptions underlying Alzai Health's expectations regarding forward-looking statements or information contained in this Presentation include, among others, Alzai Health's ability to

comply with applicable governmental regulations and standards, its success in implementing its strategies, achieving its business objectives, the ability to raise sufficient funds from equity financings in the future to support its operations, and general business and economic conditions. The foregoing list of assumptions is not exhaustive. Prospective investors reading this Presentation are cautioned that forward-looking statements are only predictions, and that Alzai Health's actual future results or performance are subject to certain risks and uncertainties including: risks related to any history of losses, which may continue in the future; risks related to increased competition and uncertainty related to additional financing that could adversely affect its ability to attract necessary capital funding, or risks related to its officers and directors becoming associated with other Artificial Intelligence (AI) or related machine learning data focused companies, which may give rise to conflicts of interest; uncertainty and volatility related to stock market prices and conditions; further equity financing(s), which may substantially dilute the interests of Alzai Health's shareholders; risks relating to its operations; dependence on general economic, market or business conditions; changes in business strategies; and changes in laws and regulations.

FORWARD-LOOKING ASSUMPTIONS/ESTIMATES in this Presentation reflects Alzai Health's current views with respect to future events and are necessarily based upon a number of assumptions and estimates that, while considered reasonable by Alzai Health, are inherently subject to significant business, economic, competitive, political and social uncertainties and contingencies. Many factors, both known and unknown, could cause actual results, performance or achievements to be materially different from the results, performance or achievements that are or may be expressed or implied by such forward-looking information contained in this Presentation and documents incorporated by reference, and we have made assumptions based on or related to many of these factors. Such factors include, without limitation: fluctuations in technology, software and health sciences markets, any future restrictions in the jurisdictions in which Alzai Health operates; laws and regulations governing our operation, research and development activities; its ability to obtain or renew approvals for the operation and expansion of its existing operations and for the development and commencement of new operations; fluctuations in currency markets (such as the US dollar versus the Canadian dollar); and its potential to impact our ability to meet its financial obligations; Alzai Health's ability to recruit and retain qualified personnel; employee relations; disputes as to the validity of scientific and proprietary titles or rights; the effectiveness of its internal control over financial reporting; claims and legal proceedings arising in the ordinary course of business activities.

Forward-looking information is made based on management's beliefs, estimates and opinions and are given only as of the date of this Presentation. Alzai Health undertakes no obligation to update forward-looking information if these beliefs, estimates and opinions or other circumstances should change, except as may be required by applicable law. Current and potential investors should not place undue reliance on forward-looking statements due to the inherent uncertainty therein. All forward-looking information is expressly qualified in its entirety by this cautionary statement.

Overview

Meeting the Unmet Need enabling Early Alzheimer's Detection, Intervention, and Prevention

Proven capability, non-invasive, low-cost with 80% sensitivity of assessing risk of being diagnosed with Alzheimer's Disease from 1 to 10 years prior to diagnosis

- **First ever AI-driven Alzheimer's risk-screening solution** using common pre-existing health data which enables population-level screening.
- **Leverages key data** available in nearly every adult medical health record worldwide, simply by applying ALZAI's custom algorithms.
- **Proof of Concept** was successfully completed. The company is now entering commercialization.
- **Strong Intellectual Property rights**, as assessed by expert legal counsel.

CRITICAL UNMET NEED: RISK SCREENING

- **Prevention:** Alzheimer's Disease can be prevented in one third of patients at-risk, if they could be identified early through Risk Screening.¹
- **Mild Cases:** Alzheimer's Disease cases can go undiagnosed until the Disease is moderate or severe, tragically losing valuable treatment time and increasing costs. Many more patients could be diagnosed and treated earlier through Risk Screening.²

1. [Alzheimer's Association](#)
2. [Alzheimer's Association](#)

Highlights



ALZAI is the first AI-driven Alzheimer's Disease risk-screening solution using 100% non-invasive, low-cost, pre-existing data enabling population-level screening.

ALZAI leverages ubiquitous data from demographics and blood panels present in nearly every adult medical record, applying proprietary suite of AI algorithms.

ALZAI can assess the risk of being diagnosed with Alzheimer's Disease from 1 to 10 years prior to diagnosis.

ALZAI's Proof of Concept was completed on 500,000 real-world patient data-sets. The company is now entering commercialization.

ALZAI Risk Screening ensures far more of the right patients move to diagnosis and treatment faster, saving both lives and money.

ALZAI solution IP is strong, as assessed by expert legal counsel including terrain review.

Diagnostic tools exist, treatment and prevention options are growing, yet screening remains a critical unmet need.

About Our Solution

ALZAI Health has created the first non-invasive risk screening solution for Alzheimer's Disease.

We aim to empower healthcare providers, payors, and clinical trial proponents with accessible, AI-powered Alzheimer's risk assessment, enabling pre-symptomatic identification & intervention.

In a perfect world, everyone over 50 would be screened for Alzheimer's Disease. ALZAI can assess risk of developing the disease, advancing pre-Alzheimer's identification to enable preventative care.

ALZAI can enable identification of people in early stages of the disease, allowing earlier diagnosis and intervention – precisely when therapies work best.

ALZAI aims to rewrite the future of Alzheimer's Disease.



Disease Overview

Alzheimer's Disease is the leading cause of dementia, accounting for up to 80% of cases.¹


Over 7 million Americans are living with Alzheimer's. This number could grow to 13.8 million by 2060.¹

Worldwide, more than 50 million people are affected, and this number will almost triple to 152 million in 2050 if no effective preventive or therapeutic solutions are found.²


Alzheimer's disease is a top 10 leading cause of death in the United States. In 2024, it was the 7th leading cause of death among U.S. adults. The actual number of people who die from Alzheimer's may be much higher than what is officially recorded.¹

Deaths attributed to Alzheimer's Disease rose more than 145% in the last 20 years.¹


Number and Ages of People 65 or Older with Alzheimer's Dementia, 2025



Percentage of People with Alzheimer's Dementia by Age Group, 2025



Projected Number of People Age 65 and Older (Total and by Age) in the U.S. Population with Alzheimer's Dementia, 2020 to 2060



Source: Alzheimer's Association

1. [Alzheimer's Association](#)
2. [National Library of Medicine](#)

Economic Impact

Nearly 12 million Americans provide unpaid care for a family member or friend with dementia, a contribution to the nation valued at more than \$413 billion.¹

In 2025 for health care, long-term care and hospice services for people with dementia are estimated to be \$384 billion. By 2050 these costs could rise to nearly 1 trillion.¹


Early detection is crucial and could save caregivers and healthcare systems approximately \$7 trillion in medical and long-term care costs for individuals.¹

Nearly
12 Million




Americans provide unpaid care for people with Alzheimer's or other dementias

Costs of Care by Payment Source for Americans Age 65 and Older with Alzheimer's or Other Dementias, 2025



Sources: Alzheimer's Association

Cost of care for individuals in the US with Alzheimer's Disease to Medicare and Medicaid from 2024 to 2050 (in billion US dollars)



1. [Alzheimer's Association](#)

Risk Screening: Public Acceptance & Demand

The growing global burden of Alzheimer's has intensified the need for early detection and precise diagnosis.

More than 9 in 10 Americans would want a simple medical test if it were available. - 91% would want testing before symptoms appear.


Four in 5 Americans (80%) indicated they would ask for a simple medical test to detect Alzheimer's rather than waiting for a doctor to suggest it.

If diagnosed with Alzheimer's disease, more than 4 in 5 Americans (83%) said they would be interested in participating in a clinical trial to evaluate a medication that would slow or cure Alzheimer's.


The global Alzheimer's disease diagnostics market size was estimated at USD 8.3 billion in 2024 and is expected to grow to 15.5 billion at a CAGR of 11.03% from 2025 to 2030.

[Source: Alzheimer's Association](#)


Perceived Importance of Early Alzheimer's Disease Diagnosis




Interest in Presymptomatic Alzheimer's Disease Testing



Interest in Postsymptomatic Alzheimer's Disease Testing



Who Would Initiate Alzheimer's Disease Testing



Source: Alzheimer's Association

Early Detection Is Crucial

Early detection of Alzheimer's opens-up crucial opportunities that can:

- ✓ make a substantial difference in outcomes.
- ✓ offer the ability to participate in clinical trials;
- ✓ access FDA-approved disease-modifying therapies
- ✓ Introduce therapies for symptom management;
- ✓ Help provide informed decisions about medical, financial and legal matters; and
- ✓ pursue appropriate services and supports.¹

People **diagnosed in the earlier stages** of Alzheimer's disease are the **only ones** for whom the new anti-amyloid medications donanemab (Kisunla™) and lecanemab (Leqembi®) are approved.¹

Nearly every major Pharma company has a product pipeline for Alzheimer's therapies and related preventatives which **require quality risk screening** to advance clinical trials.²

1. [Alzheimer's Association](#)
2. [Grandview Research](#)


The Problem

Early-Stage Alzheimer's Disease (AD) remains widely undiagnosed due to the absence of risk screening, delaying intervention and treatment.

SCREENING TODAY RELIES ON PHYSICIAN SUSPICION

Without systematic risk screening, early intervention is rare, and treatment is delayed.

Current tests, such as magnetic resonance imaging (MRI), and biochemical quantification of proteins in cerebrospinal fluid are expensive, time-consuming and invasive, and cannot be used on a large population.²



1. [Alzheimer's Association](#)
2. [Nature](#)

The Solution

ALZAI's AI-Powered Risk Screening for Alzheimer's Disease


ALZAI uses existing **Electronic Medical Records (EMR)** and AI to seamlessly screen populations, identifying high-risk patients.

By providing valuable clinical decision support for physicians, ALZAI enables early diagnosis and treatment for the ill, and preventative care for those at-risk.

80-90%

Mild AD/MCI*
cases identified

*AD: Alzheimer's Disease
MCI: Mild Cognitive Impairment



ALZAI Risk Assessment

Seamless Screening Experience
Built on a user-friendly, easily integrated platform for healthcare providers, clinical researchers, and stakeholders.

Standard integration with Electronic Medical Record (EMR) systems.

Provides at-risk screening stratified by year and quantified by confidence level.



Risk of AD Diagnosis: **Yes**


Patient Name: Patient ID #: Insurance #:

Assessment Date: Previous Assessment Date: Age: Sex:

Risk Timeframe			Confidence Level	Change From Previous
Probable Undiagnosed Disease	Year 1-3	No	Low Medium High	No Change
High Risk of Developing Disease	Year 4-6	Yes	Low Medium High	Improved
High Risk of Developing Disease	Year 7-10	Yes	Low Medium High	No Change

Our Customers, Partners & Stakeholders

Clinical Risk-Screening for Healthcare



Population-level
Alzheimer's
risk-screening

Identifying at-risk
individuals early
enables proactive
intervention and
major cost savings

Large Health Systems & Institutions,
Lab Services and Insurance Companies

Recruitment Pre-Screening for Clinical Trials



Reduces screening
failure rates
dramatically

A major cost and time
bottleneck in Alzheimer's
Disease clinical trials

Accelerates recruitment
for therapeutic and
preventative clinical trials

Pharma Companies, Clinical Research
Organizations, Institutions & Sponsors

Clinical Risk-Screening Market

For Healthcare Providers and Payors

Target Users



Large Health Systems & Institutions (e.g. Mayo Clinic, Kaiser Permanente)



Diagnostic & Lab Services (eg. Life Labs)



Insurance Companies
Risk assessment & early detection to lower costs.

Market & Business Model



Regulatory: Moderate burden, 510(k) Clinical Decision Support Tool, ~24-month timeline



Business Models: Pay-per-screen & annual licensing



ALZAI is Changing the Future of Alzheimer's Disease Screening!

30%

Reduction in subjects developing AD with early intervention¹

30 to 40%

Slower Disease Progression with therapeutic intervention²

\$8.3B

AD Diagnostic Market (2024)³

\$7.9T

Global Savings if early detection for people alive in 2018⁴

11.03%


CAGR Growth (2025-2030)³

1. [Alzheimer's Association](#)
2. [The Guardian](#)
3. [Grandview Research](#)
4. [Alzheimer's Association](#)

ALZAI Clinical Risk Screening Impact

Among an example 2.8M population over the age of 60
280,000 persons are living with Mild AD or MCI.

High-precision risk screening leading to diagnosis and treatment could save over \$64,000 per patient¹;
Prevention can reduce Alzheimer's Disease cases by 30%.²



Clinical Risk Screening: Market Scope


The global Alzheimer's disease diagnostics market size was estimated at USD 8.3 billion in 2024 and is expected to grow to 15.5 billion at a CAGR of 11.03% from 2025 to 2030.

In 2024, the academic and research institutes segment led the end use market, holding the largest share at 48%. Hospitals 32%, Diagnostic Laboratories 20%. The biomarkers segment is expected to witness the fastest growth over the forecast period.

North America Alzheimer's disease diagnostics industry held the worlds largest share of 47.63% in 2024. The region is also leading in Alzheimer's disease biomarker research.


Alzheimer's Disease Diagnostics Market

Size by Diagnostics Technique, 2024 - 2030 USD billion




Alzheimer's Disease Diagnostic Market

Share, by End-use, 2024 (%)



Alzheimer's Disease Diagnostic Market

Trends, by Region, 2025 - 2030



Recruitment for Clinical Trials Market


For Clinical Trial Sponsors, Researchers and Service Companies

Addresses a key need in Alzheimer's drug development, optimizing clinical trial efficiency and reduces costs.

Target Users



Pharmaceutical Companies
Enhance drug development
efficiency and success rates




Clinical Research
Organizations (CROs)
Streamline patient recruitment
and optimization



Research Institutions &
Sponsors
Improves trial design and
participant selection

Market & Business Model



Regulatory: No significant
burden, FDA 510(k) not
required for implementation



Revenue Model: Licensing
ALZAI solutions plus
professional services for
data integration and tuning



Immediate Commercialization
Ready for product
development without lengthy
approval processes

\$5.6B Estimated investment in
AD drug development
programs¹

\$8-12k Cost per screening, Risk,
Expense, and Delay-to-
market²

~3 yrs Timeline for trial
recruitment

187+ Ongoing AD trials as of
2023 with more in
pre-clinical phases


141 Assessed drugs for the
treatment of AD³

1. National Library of Medicine: <https://pmc.ncbi.nlm.nih.gov/articles/PMC6118094/>
2. Source: Grandview Research: <https://www.grandviewresearch.com/industry-analysis/alzheimers-disease-diagnostics-market-report>
3. National Library of Medicine: <http://pmc.ncbi.nlm.nih.gov/articles/PMC10210334/>

ALZAI Risk-Screening for Clinical Trial Impact

Clinical trial sponsors, Clinical Research Organizations (CROs) and service companies

High-precision risk pre-screening reduces screened subjects by 10,000, cutting the cost by \$30-\$40M, while lowering screen failure rates, and completing trials at least a year faster than the standard 3-year timeline.



Company Status

Proof-of-Concept is Established; Alzai is Commercial-Ready




Advanced Learning & Data Foundation

ALZAI uses machine learning models using EMR from Clalit Health Services. Over 330,000 patients were selected from the database, of whom 41,300 were diagnosed with AD.



Proven Predictive Accuracy

ALZAI identifies 80-90% of at-risk patients up to 10 years before diagnosis. This non-invasive, cost-effective approach enables early intervention, improving patient outcomes.



Intellectual Property & Legal Standing

ALZAI has a strong IP strategy with a filed PCT, securing legal protection. Continuous expansion reinforces exclusivity and ensures ongoing innovation in AI-driven screening.



Market Readiness & Customization

With proof-of-concept established and real-world validation, ALZAI is commercial-ready. The core product is customizable and adapts to various healthcare systems worldwide.

Intellectual Property

ALZAI's Strong Intellectual Property Foundation

ALZAI holds exclusive rights to all intellectual property generated through its research and innovation:


- ✓ Original Research IP: The foundation of ALZAI's technology
- ✓ New IP Developed by ALZAI: Innovations emerging from ongoing research and development
- ✓ IP from Future Research: Any advancements based on the original IP remain under ALZAI's ownership

ALZAI's intellectual property has been rigorously assessed by top legal experts, ensuring a strong legal position:

- ✓ Ehrlich Law (Israel's Leading IP Firm): Created ALZAI's PCT* and confirmed no prior art
- ✓ Calyx Law (California-based IP Specialists): Reviewed IP landscape, confirming ALZAI's strong legal position

*Patent Cooperation Treaty (PCT) makes it possible to seek patent protection for an invention simultaneously in each of a large number of countries by filing an "international" patent application.

Leadership



Hayim Raclaw

Director, Chief Executive Officer
& Co-founder

An experienced founder and executive with 25 years in medical technologies, including imaging, diagnostics, surgery, mental health, and venture capital. Proven track record of creating value through strategic leadership.



Roy Kait

Director, Chief Revenue Officer
& Co-founder

Over 15 years in startups, finance, and strategy across Israel, Europe, the US, Canada, and LATAM, including M&A leadership at IMC (NASDAQ: IMCC, CSE: IMCC) with \$180M+ in transactions. Reserve pilot in the Israeli Air Force.



Dr. Amir Glik, MD

Director, Chief Medical Officer
& Co-founder

Senior Neurologist at Clalit Health Services in Israel and Head of the Cognitive Neurology Service at Beilinson Hospital, Rabin Medical Center, part of the Clalit network. Holds multiple registered patents across various research projects in cognitive neurology.




Dr. Chen Hajaj

Director, Data Science
& Co-founder

Founder of the Data Science and AI Research Center and faculty member in the Department of Industrial Engineering and Management at Ariel University. A recognized expert in machine learning, with extensive research and applied AI experience.

Expert Advisors



Dr. Michael Greenberg, MD
Neurosurgeon, Entrepreneur, PubCo
CEO, Experienced company developer

Med-Tech CEO who led a medical imaging company to NASDAQ & TSX IPO before its \$500M acquisition by IBM. Co-founded Fio Corporation, pioneering Fionet for diagnostics. MD from UPenn, neurosurgery residency and NIH post-doc at UofT.



Prof. Lindsay A. Farrer, Ph.D.
Leading NIH-funded programs,
identified causal factors for AD

Chief of Biomedical Genetics at Boston University. Led NIH-funded research identifying genetic risk factors for Alzheimer's. PI of the Framingham Heart Study – Brain Aging Program. Authored 500+ publications. Ph.D. from Indiana University, post-doc at Yale.



Uri Bettesh
Founder & CEO of Datos, Patient
Engagement Platform for Healthcare

Founder & CEO of Datos, a leading patient engagement platform used by Kaiser Permanente and Mayo Clinic. Former GM at NCR and VP at Retalix, with 18 years as a technology executive. BSc and Master's in Engineering from Technion.



Thank You

ALZAI Health Corp.
100 King St. West, Suite 1600
Toronto, ON., M5X 1G5 Canada
Phone: +1 (416) 862 4351

info@alzaihealth.com
www.alzaihealth.com

ALZAI HEALTH CORPORATION | PRESENTATION 2025



Predictive
Alzheimer's Risk
Screening through
the Power of AI